Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Crinetics Pharmaceuticals Inc operates as a clinical stage pharmaceutical company. The Company develops therapeutics for the treatment of endocrine diseases and cancers. Crinetics Pharmaceuticals serves clients in the State of California.
Website: crinetics.com



Growth: Bad revenue growth rate 0.0%, are preserved at an average historical level 0.0%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is positive, +66.7%. Gross margin is high, +100.0%. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.06 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield -6.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 102.4% higher than minimum and 48.9% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.7x by EV / Sales multiple , the company can be 99.1% overvalued

Insiders: For the last 3 months insiders sold company shares on $3.1 mln (-0.182% of cap.)

Key Financials (Download financials)

Ticker: CRNX
Share price, USD:  (+1.9%)30.99
year average price 42.70  


year start price 54.36 2024-07-27

max close price 60.69 2024-11-08

min close price 25.56 2025-04-08

current price 30.99 2025-07-26
Common stocks: 53 505 799

Dividend Yield:  0.0%
FCF Yield LTM: -6.9%
EV / LTM EBITDA: 799.1x
EV / Sales: 532.7x
Margin (EBITDA LTM / Revenue): 66.7%
Fundamental value created in LTM:
Market Cap ($m): 1 658
Net Debt ($m): -60
EV (Enterprise Value): 1 598
Price to Book: 2.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-05-10seekingalpha.com

Crinetics Pharmaceuticals, Inc (CRNX) Q1 2025 Earnings Call Transcript

2025-05-08zacks.com

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q1 Loss, Tops Revenue Estimates

2025-04-02seekingalpha.com

Crinetics Pharma: Strong Progress With Multiple Indications And Upcoming PDUFA

2025-02-06globenewswire.com

Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025

2025-01-02seekingalpha.com

Crinetics Pharmaceuticals: Attractive Speculative Bet On Market Weakness

2024-11-12seekingalpha.com

Crinetics Pharmaceuticals, Inc. (CRNX) Q3 2024 Earnings Call Transcript

2024-10-08globenewswire.com

Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock

2024-08-08zacks.com

Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates

2024-07-18globenewswire.com

Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024

2024-06-18globenewswire.com

EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-08-08 2024-05-09 2023-12-31 2023-11-07 2023-08-08 2023-05-09 2023-02-28 2022-11-14
acceptedDate 2024-11-12 16:15:13 2024-08-08 16:13:11 2024-05-09 16:38:18 2023-12-29 19:00:00 2023-11-07 16:11:27 2023-08-08 07:07:10 2023-05-09 16:56:05 2023-02-28 16:26:50 2022-11-14 08:31:12
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 0 399 000 640 000 0 346 000 988 000 3M 709 000 458 000
costOfRevenue 0 753 000 474 000 262 000 273 000 398 000 0 0 0
grossProfit 0 -354 000 166 000 -262 000 73 000 590 000 3M 709 000 458 000
grossProfitRatio 0 -0.887 0.259 0 0.211 0.597 1 1 1
researchAndDevelopmentExpenses 62M 58M 53M 45M 44M 41M 38M 37M 32M
generalAndAdministrativeExpenses 26M 25M 21M 17M 15M 13M 12M 11M 12M
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 26M 25M 21M 17M 15M 13M 12M 11M 12M
otherExpenses 0 0 -251 000 40 000 3M -91 000 2M 3M 0
operatingExpenses 88M 83M 74M 62M 59M 54M 51M 48M 44M
costAndExpenses 88M 83M 74M 63M 59M 54M 51M 48M 44M
interestIncome 11M 9M 7M 7M 3M 2M 2M 2M 2M
interestExpense 0 0 0 0 0 0 -2M 2M 2M
depreciationAndAmortization 770 000 753 000 474 000 262 000 273 000 280 000 283 000 280 000 248 000
ebitda -87M -82M -74M -62M -59M -53M -48M -48M -43M
ebitdaratio 0 -205.589 -115.148 0 -170.454 -53.355 -17.909 -67.075 -94.336
operatingIncome -88M -83M -74M -63M -59M -53M -48M -48M -43M
operatingIncomeRatio 0 -207.476 -115.889 0 -170.454 -53.639 -17.909 -67.075 -94.878
totalOtherIncomeExpensesNet 11M 9M 7M 3M 2M -91 000 2M 3M 2M
incomeBeforeTax -77M -74M -67M -60M -57M -51M -46M -45M -42M
incomeBeforeTaxRatio 0 -185.602 -104.578 0 -166.064 -51.598 -17.169 -63.457 -91.539
incomeTaxExpense 0 0 -1 218 188 -273 000 -2M -2M -3M -2M
netIncome -77M -74M -67M -60M -57M -51M -44M -42M -40M
netIncomeRatio 0 -185.602 -104.578 0 -166.064 -51.598 -16.429 -59.839 -88.201
eps -0.96 -0.94 -0.93 -0.9 -1.01 -0.94 -0.82 -0.79 -0.75
epsdiluted -0.96 -0.94 -0.93 -0.9 -1.01 -0.94 -0.82 -0.79 -0.75
weightedAverageShsOut 80M 79M 72M 67M 57M 54M 54M 54M 54M
weightedAverageShsOutDil 80M 79M 72M 67M 57M 54M 54M 54M 54M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-08-08 2024-05-09 2023-12-31 2023-11-07 2023-08-08 2023-05-09 2023-02-28 2022-11-14
acceptedDate 2024-11-12 16:15:13 2024-08-08 16:13:11 2024-05-09 16:38:18 2023-12-29 19:00:00 2023-11-07 16:11:27 2023-08-08 07:07:10 2023-05-09 16:56:05 2023-02-28 16:26:50 2022-11-14 08:31:12
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 317M 302M 396M 55M 143M 40M 41M 33M 31M
shortTermInvestments 545M 561M 505M 504M 412M 225M 255M 302M 337M
cashAndShortTermInvestments 863M 863M 901M 559M 555M 265M 296M 334M 368M
netReceivables 7M 5M 9M 9M 12M 2M 2M 2M 2M
inventory 0 0 0 0 -12M 15M -2M 0 0
otherCurrentAssets 8M 7M 7M 6M 21M 3M 9M 8M 2M
totalCurrentAssets 878M 875M 917M 574M 576M 285M 305M 345M 378M
propertyPlantEquipmentNet 56M 57M 58M 57M 58M 4M 5M 5M 5M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 0 0
longTermInvestments 0 2M 1M 2M 6M 2M 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 4M 2M 2M 2M 2M 2M 4M 2M 1M
totalNonCurrentAssets 60M 61M 61M 61M 66M 8M 9M 7M 7M
otherAssets 0 0 0 1 0 1000 0 0 0
totalAssets 937M 936M 978M 635M 642M 293M 314M 352M 385M
accountPayables 5M 9M 11M 7M 6M 5M 6M 7M 6M
shortTermDebt 7M 15M 6M 4M 4M 1M 1M 0 1M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 2M 3M 2M 2M 2M 2M 2M 2M 2M
otherCurrentLiabilities 40M 28M 33M 31M 29M 25M 17M 19M 15M
totalCurrentLiabilities 54M 54M 52M 44M 40M 33M 26M 28M 25M
longTermDebt 45M 46M 47M 48M 48M 1M 2M 2M 2M
deferredRevenueNonCurrent 0 4M 5M 5M 5M 5M 6M 6M 7M
deferredTaxLiabilitiesNonCurrent 0 0 0 -48M -5M 0 0 0 0
otherNonCurrentLiabilities 6M 202 000 -1 48M 5M 0 0 0 -267 000
totalNonCurrentLiabilities 51M 50M 51M 52M 53M 7M 7M 8M 9M
otherLiabilities 0 0 1 0 0 0 0 0 0
capitalLeaseObligations 53M 53M 47M 48M 52M 3M 3M 2M 3M
totalLiabilities 104M 105M 103M 96M 94M 39M 34M 36M 34M
preferredStock 0 0 0 0 0 0 0 0 0
commonStock 1 702M 1 626M 1 595M 1 192M 1 142M 792M 768M 759M 751M
retainedEarnings -872M -795M -721M -654M -594M -536M -485M -439M -394M
accumulatedOtherComprehensiveIncomeLoss 2M -190 000 150 000 977 000 -865 000 -2M -3M -4M -5M
othertotalStockholdersEquity 0 0 0 0 -1 141M 0 -765M -756M 0
totalStockholdersEquity 833M 831M 875M 539M -594M 254M -485M -439M 351M
totalEquity 833M 831M 875M 539M -594M 254M -485M -439M 351M
totalLiabilitiesAndStockholdersEquity 937M 936M 978M 635M -500M 293M -451M -403M 385M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 937M 936M 978M 635M -500M 293M -451M -403M 385M
totalInvestments 545M 562M 506M 505M 412M 225M 255M 302M 337M
totalDebt 53M 53M 53M 52M 52M 3M 3M 2M 3M
netDebt -265M -249M -343M -3M -91M -37M -38M -31M -28M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX CRNX
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2024-11-12 2024-08-08 2024-05-09 2023-12-31 2023-11-07 2023-08-08 2023-05-09 2023-02-28 2022-11-14
acceptedDate 2024-11-12 16:15:13 2024-08-08 16:13:11 2024-05-09 16:38:18 2023-12-29 19:00:00 2023-11-07 16:11:27 2023-08-08 07:07:10 2023-05-09 16:56:05 2023-02-28 16:26:50 2022-11-14 08:31:12
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -77M -74M -67M -60M -57M -51M -46M -45M -42M
depreciationAndAmortization 770 000 753 000 474 000 262 000 273 000 280 000 283 000 280 000 248 000
deferredIncomeTax 0 0 0 -8M -7M -905 000 0 0 0
stockBasedCompensation 18M 19M 13M 12M 11M 10M 8M 8M 7M
changeInWorkingCapital -14M 11M 3M 8M 5M -4M -687 000 2M -4M
accountsReceivables 0 0 0 0 0 0 0 0 0
inventory 0 0 0 0 0 0 0 0 0
accountsPayables 0 7M 1M 4M 4M 7M -1M 3M 0
otherWorkingCapital -14M 4M 1M 4M 470 000 -12M 658 000 -385 000 -4M
otherNonCashItems 9M -3M 11M 9M 7M 118 000 -2M -812 000 -29 000
netCashProvidedByOperatingActivities -63M -46M -53M -39M -41M -46M -41M -35M -38M
investmentsInPropertyPlantAndEquipment -528 000 -955 000 -1M -935 000 -4M -237 000 -16 000 -274 000 -682 000
acquisitionsNet 0 0 0 86M 190M -32M -530 000 34 000 0
purchasesOfInvestments -141M -192M -100M -173M -278M -59M -23M -34M -49M
salesMaturitiesOfInvestments 151M 139M 101M 87M 88M 91M 71M 71M 56M
otherInvestingActivites 11M 0 2M -86M -190M 32M 530 000 -34 000 0
netCashUsedForInvestingActivites 21M -54M 309 000 -87M -193M 31M 49M 37M 7M
debtRepayment 0 0 0 0 0 0 0 0 0
commonStockIssued 47M -4M 394M 38M 338M 13M 484 000 0 -13 000
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 11M 5M 394M 38M 338M 0 0 115 000 1M
netCashUsedProvidedByFinancingActivities 57M 5M 394M 38M 338M 13M 484 000 115 000 1M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 0
netChangeInCash 16M -94M 341M -88M 103M -2M 9M 2M -31M
cashAtEndOfPeriod 319M 302M 396M 55M 143M 41M 42M 34M 32M
cashAtBeginningOfPeriod 302M 396M 55M 143M 40M 42M 34M 32M 63M
operatingCashFlow -63M -46M -53M -39M -41M -46M -41M -35M -38M
capitalExpenditure -528 000 -955 000 -1M -935 000 -4M -237 000 -16 000 -274 000 -682 000
freeCashFlow -63M -47M -54M -39M -45M -46M -41M -35M -39M
link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-12 ET (fiscal 2024 q3)
2024 q2
2024-08-08 ET (fiscal 2024 q2)
2024 q1
2024-05-11 ET (fiscal 2024 q1)
2023 q4
2024-02-29 ET (fiscal 2023 q4)

Press-releases

Show financial reports only

2024-11-12 21:07 ET
Crinetics Pharmaceuticals to Showcase Pipeline Advancements with Neuroendocrine Tumor Candidates at The North American Neuroendocrine Tumor Society (NANETS) Annual Meeting
2024-11-12 21:05 ET
Crinetics Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
2024-11-11 21:05 ET
Crinetics Pharmaceuticals Announces November 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-10-16 12:00 ET
Crinetics Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 12, 2024
2024-10-10 20:40 ET
Crinetics Pharmaceuticals Announces October 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-10-09 03:55 ET
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
2024-10-08 20:01 ET
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
2024-09-26 20:05 ET
Crinetics Submits New Drug Application for Paltusotine for the Treatment of Acromegaly
2024-09-10 20:40 ET
Crinetics Pharmaceuticals Announces September 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-29 20:05 ET
Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences
2024-08-12 20:05 ET
Crinetics Pharmaceuticals Announces August 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-08-08 20:05 ET
Crinetics Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
2024-08-08 12:30 ET
Crinetics Launches ACRO/TRUTH Educational Initiative to Raise Awareness of Acromegaly Treatment Challenges
2024-07-18 20:05 ET
Crinetics Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024
2024-07-10 23:29 ET
Crinetics Pharmaceuticals Announces July 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-06-18 20:30 ET
EY Announces Scott Struthers, Ph.D., CEO and Founder of Crinetics Pharmaceuticals, as an Entrepreneur Of The Year® 2024 Pacific Southwest Award Winner
2024-06-10 22:35 ET
Crinetics Pharmaceuticals Announces June 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-06-03 16:00 ET
Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS)
2024-06-03 16:00 ET
Crinetics Presents New Data at ENDO 2024 that Increases Body of Evidence Positioning Once-Daily, Oral Paltusotine as Potential First-Choice Treatment Option for Acromegaly
2024-05-30 20:05 ET
Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affairs
2024-05-22 12:00 ET
Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts
2024-05-10 21:38 ET
Crinetics Pharmaceuticals Announces May 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-05-09 20:05 ET
Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
2024-05-08 20:05 ET
Crinetics Pharmaceuticals to Present Advancements from Atumelnant (CRN04894) and Paltusotine Development Programs at ENDO 2024
2024-05-02 20:05 ET
Crinetics Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024
2024-04-11 20:05 ET
Crinetics Pharmaceuticals Announces April 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-03-19 10:00 ET
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients
2024-03-12 20:05 ET
Crinetics Announces Positive Topline Results from Phase 2 Trial of Paltusotine for the Treatment of Carcinoid Syndrome
2024-03-11 20:05 ET
Crinetics Pharmaceuticals Announces March 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-02-28 21:05 ET
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
2024-02-28 13:00 ET
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
2024-02-28 13:00 ET
Crinetics Pharmaceuticals Announces Oversubscribed $350 Million Private Placement
2024-02-14 21:05 ET
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024
2024-02-12 21:05 ET
Crinetics Pharmaceuticals Announces February 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-10 21:33 ET
Crinetics Pharmaceuticals Announces January 2024 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2024-01-03 13:00 ET
Crinetics Pharmaceuticals to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
2024-01-03 12:00 ET
Radionetics Oncology Raises $52.5 Million Series A to Advance First-in-Class Radiopharmaceutical Pipeline and Announces the Appointment of Industry Leader, Paul Grayson, as CEO
2023-12-18 21:05 ET
Crinetics Announces Positive Initial Findings from Ongoing Open-Label Phase 2 Study of Paltusotine for the Treatment of Carcinoid Syndrome
2023-12-11 21:05 ET
Crinetics Pharmaceuticals Announces December 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-20 21:05 ET
Crinetics Pharmaceuticals to Participate in Upcoming Investor Conferences
2023-11-10 22:00 ET
Crinetics Pharmaceuticals Announces November 2023 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-07 21:05 ET
Crinetics Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
2023-10-17 14:15 ET
GordonMD® Announces Investment in Radiopharmaceutical Biotech Radionetics Oncology
2023-10-10 21:00 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-20 12:00 ET
Crinetics Pharmaceuticals to Participate in the Cantor Global Healthcare Conference 2023
2023-09-13 02:26 ET
Crinetics Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock
2023-09-11 20:01 ET
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
2023-09-11 10:00 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-09-10 14:00 ET
Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-1 Study Evaluating Treatment of Patients with Acromegaly
2023-08-10 21:34 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-08-08 11:00 ET
Crinetics Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Corporate Update
2023-07-31 12:01 ET
Crinetics Hosting Key Opinion Leader Webinar to Discuss the Current Treatment Landscape and Unmet Need in Acromegaly
2023-07-10 20:18 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-21 11:59 ET
New Data Demonstrating Stable Biochemical and Symptom Levels with Two-Years of Oral Paltusotine Administration Presented at ENDO 2023
2023-06-12 11:30 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-06-09 11:30 ET
Crinetics to Highlight Broad Pipeline at ENDO 2023
2023-05-10 20:21 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-05-04 20:05 ET
Crinetics Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update
2023-04-10 20:31 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-03-10 21:37 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-02-28 21:05 ET
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
2023-02-10 22:21 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-02-10 13:01 ET
Crinetics Pharmaceuticals to Participate in the SVB Securities Global Biopharma Conference
2023-01-10 21:48 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-01-09 13:01 ET
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference
2022-12-12 21:01 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-11-28 13:00 ET
Crinetics Pharmaceuticals Provides Update on CRN04777 Program
2022-11-22 13:00 ET
Crinetics Pharmaceuticals to Participate in the 5th Annual Evercore ISI HealthCONx Conference
2022-11-14 13:00 ET
Crinetics Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
2022-11-10 21:30 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-10-13 12:00 ET
Enrollment Completed in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
2022-10-10 20:57 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-10-06 12:00 ET
Innovation Passport Granted for CRN04777 for the Treatment of Congenital Hyperinsulinism
2022-10-03 12:00 ET
Crinetics Pharmaceuticals Appoints Dana Pizzuti, M.D. as Chief Development Officer
2022-09-12 12:00 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-09-08 12:00 ET
Crinetics Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
2022-09-06 12:00 ET
New Long-Term Safety and Efficacy Data Presented with Paltusotine in Participants Living with Acromegaly
2022-09-02 12:00 ET
New Long-Term Safety and Efficacy Data for Investigational Compound Paltusotine to be Presented at the Brazilian Congress of Endocrinology and Metabolism
2022-08-12 12:00 ET
Crinetics Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
2022-08-10 20:44 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-08-04 12:00 ET
Additional Analyses of CRN04894 Preclinical and Phase 1 Results to be Presented at the 10th International Congress of Neuroendocrinology
2022-07-12 21:09 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-10 20:30 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-06-08 11:30 ET
Crinetics Presents Clinical and Research Results at ENDO 2022
2022-06-07 11:30 ET
Crinetics Pharmaceuticals to Participate in the JMP Securities Life Sciences Conference
2022-05-25 11:00 ET
Crinetics Pharmaceuticals Reports Positive Top-line Results Including Strong Adrenal Suppression from CRN04894 Phase 1 Study Multiple-Ascending Dose Cohorts
2022-05-12 20:41 ET
Crinetics Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
2022-05-10 20:18 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-04-18 20:01 ET
Crinetics Pharmaceuticals Announces Closing of Underwritten Common Stock Offering
2022-04-13 03:50 ET
Crinetics Pharmaceuticals Announces Pricing of Underwritten Common Stock Offering
2022-04-11 21:15 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-03-30 20:02 ET
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results
2022-03-30 20:01 ET
Crinetics Pharmaceuticals Reports Positive Top-Line Results from CRN04777 Phase 1 Study Multiple-Ascending Dose Cohorts
2022-03-21 11:30 ET
Crinetics Pharmaceuticals Appoints Chris Robillard as Chief Business Officer
2022-03-14 11:30 ET
Crinetics Pharmaceuticals Appoints Caren Deardorf to Board of Directors
2022-03-10 22:20 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-03-01 13:00 ET
Crinetics Pharmaceuticals Expands Executive Team with Appointment of James Hassard as Chief Commercial Officer
2022-02-28 11:00 ET
Crinetics Pharmaceuticals and Sanwa Kagaku Kenkyusho Enter into Exclusive Licensing Agreement for the Development and Commercialization of Paltusotine in Japan
2022-02-09 12:30 ET
Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference
2022-02-01 21:42 ET
Crinetics Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2022-01-12 12:30 ET
Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 40th Annual J.P. Morgan Healthcare Conference
2022-01-05 12:30 ET
Crinetics Pharmaceuticals Adds Board Member with Global Rare Disease Expertise with Appointment of Rogério Vivaldi Coelho, M.D., M.B.A.
2021-11-18 13:00 ET
Crinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI HealthCONx Conference
2021-11-08 13:00 ET
Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress
2021-11-05 12:00 ET
Crinetics Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Corporate Update
2021-10-25 20:01 ET
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2021-10-21 12:22 ET
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2021-10-20 20:01 ET
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
2021-10-18 20:00 ET
Radionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology
2021-09-27 11:30 ET
Crinetics Pharmaceuticals to Unveil its Parathyroid Hormone Receptor Antagonist Program at the American Society for Bone and Mineral Research Annual Meeting
2021-09-15 20:01 ET
Crinetics Pharmaceuticals’ Oral SST5 Agonist CRN04777 Demonstrated Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study
2021-09-07 11:30 ET
Crinetics Pharmaceuticals to Participate in September Investor Conferences
2021-09-02 11:30 ET
Crinetics Pharmaceuticals Expands Executive Team with Addition of Jeff Knight as Chief Operating Officer
2021-08-10 20:02 ET
Crinetics Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Corporate Update
2021-08-10 20:01 ET
Crinetics Pharmaceuticals’ Oral ACTH Antagonist, CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Dose-Dependent Cortisol Suppression in Single Ascending Dose Portion of Phase 1 Study
2021-07-29 11:30 ET
Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners
2021-06-28 11:30 ET
Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
2021-06-16 12:30 ET
Crinetics Pharmaceuticals Appoints Garlan Adams as General Counsel
2021-05-06 20:05 ET
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
2021-04-12 20:05 ET
Crinetics Pharmaceuticals Announces Closing of Common Stock Offering
2021-04-07 22:31 ET
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2021-03-30 20:05 ET
Crinetics Pharmaceuticals Announces 2021 Clinical Plans and Reports Fourth Quarter and Full Year 2020 Financial Results
2021-03-24 11:10 ET
Crinetics Pharmaceuticals to Host Webcast and Conference Call to Discuss 2021 Clinical Plans and Fourth Quarter and Full Year 2020 Financial Results
2021-03-22 11:10 ET
Crinetics Pharmaceuticals Pipeline Progress on Display at ENDO 2021
2021-03-12 12:10 ET
Crinetics Pharmaceuticals Showcasing Breadth of Pipeline at ENDO 2021 with Presentations on Three Clinical Programs
2021-02-04 12:10 ET
Crinetics Pharmaceuticals Lead ACTH Antagonist for Congenital Adrenal Hyperplasia and Cushing’s Disease (CRN04894) Advances into Phase 1 Study
2021-02-03 12:10 ET
Crinetics Pharmaceuticals Advances CRN04777 for Congenital Hyperinsulinism into Phase 1 Study
2021-01-06 12:05 ET
Crinetics Pharmaceuticals to Review 2020 Accomplishments and Provide 2021 Plans at 39th Annual J.P. Morgan Healthcare Conference 
2020-11-23 12:30 ET
Crinetics Pharmaceuticals to Participate in December Investor Conferences
2020-11-16 12:30 ET
Crinetics Pharmaceuticals Appoints Acromegaly Expert, Peter Trainer, Vice President of Clinical Endocrinology
2020-11-13 12:30 ET
Crinetics Hosting Key Opinion Leader Meeting Focusing on Oral Paltusotine for the Treatment of Acromegaly
2020-11-06 13:31 ET
Crinetics Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Corporate Update
2020-10-26 11:02 ET
Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint
2020-09-21 11:30 ET
Crinetics Pharmaceuticals Receives Rare Pediatric Disease Designation from FDA for CRN04777 for the Treatment of Congenital Hyperinsulinism
2020-09-04 11:30 ET
Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology
2020-09-03 21:56 ET
Crinetics Pharmaceuticals to Participate in September Investor Conferences
2020-09-03 11:30 ET
Crinetics Pharmaceuticals Appoints Rare Disease Executive, Camille L. Bedrosian, M.D., to Board of Directors
2020-08-07 11:30 ET
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
2020-07-08 20:05 ET
Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly
2020-06-11 11:30 ET
Crinetics Pharmaceuticals Confirms Completion for Half of the Enrolled Patients in the Ongoing Phase 2 ACROBAT Edge Clinical Trial for Paltusotine
2020-05-27 11:30 ET
Crinetics Pharmaceuticals Appoints Adriana Cabré, MBA, as Vice President of Human Resources
2020-05-08 13:01 ET
Crinetics Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
2020-04-17 20:05 ET
Crinetics Pharmaceuticals Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2020-04-15 04:21 ET
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
2020-04-14 20:05 ET
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
2020-04-06 20:30 ET
Crinetics Pharmaceuticals Reports Positive Interim Results for the ACROBAT Edge Phase 2 Trial of Paltusotine (CRN00808) in Acromegaly Patients and Provides Corporate Update
2020-03-09 20:10 ET
Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update
2020-02-19 12:30 ET
Crinetics Pharmaceuticals to Participate in SVB Leerink Global Healthcare Conference
2020-01-08 12:30 ET
Crinetics Pharmaceuticals to Present at J.P. Morgan Healthcare Conference
2019-11-26 21:05 ET
Crinetics Pharmaceuticals to Participate in the Piper Jaffray Healthcare Conference
2019-11-12 21:04 ET
Crinetics Pharmaceuticals Reports Third Quarter 2019 Financial Results and Provides Corporate Update
2019-09-25 11:30 ET
Crinetics Pharmaceuticals to Participate in Cantor Global Healthcare Conference

SEC forms

Show financial reports only

SEC form 8
2025-06-30 20:26 ET
Crinetics Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-30 20:26 ET
Crinetics Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-26 20:16 ET
Crinetics Pharmaceuticals published news for 2025 q1
SEC form 8
2025-06-26 20:16 ET
Crinetics Pharmaceuticals published news for 2025 q1
SEC form 10
2025-05-08 20:14 ET
Crinetics Pharmaceuticals reported for 2025 q1
SEC form 8
2025-05-08 20:09 ET
Crinetics Pharmaceuticals published news for 2025 q1
SEC form 8
2025-05-08 20:09 ET
Crinetics Pharmaceuticals reported for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Crinetics Pharmaceuticals reported for 2025 q1
SEC form 10
2025-02-27 16:13 ET
Crinetics Pharmaceuticals reported for 2024 q4
SEC form 8
2025-02-27 16:10 ET
Crinetics Pharmaceuticals published news for 2024 q4
SEC form 8
2025-02-27 16:10 ET
Crinetics Pharmaceuticals published news for 2024 q4
SEC form 10
2025-02-27 00:00 ET
Crinetics Pharmaceuticals reported for 2024 q4
SEC form 10
2024-11-12 16:15 ET
Crinetics Pharmaceuticals reported for 2024 q3
SEC form 8
2024-11-12 16:08 ET
Crinetics Pharmaceuticals published news for 2024 q3
SEC form 8
2024-11-12 16:08 ET
Crinetics Pharmaceuticals published news for 2024 q3
SEC form 10
2024-08-08 16:13 ET
Crinetics Pharmaceuticals reported for 2024 q2
SEC form 8
2024-08-08 16:10 ET
Crinetics Pharmaceuticals published news for 2024 q2
SEC form 8
2024-08-08 16:10 ET
Crinetics Pharmaceuticals reported for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Crinetics Pharmaceuticals reported for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Crinetics Pharmaceuticals reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Crinetics Pharmaceuticals published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Crinetics Pharmaceuticals reported for 2024 q1
SEC form 10
2024-02-28 16:15 ET
Crinetics Pharmaceuticals reported for 2023 q4
SEC form 8
2024-02-28 16:09 ET
Crinetics Pharmaceuticals published news for 2023 q4
SEC form 8
2024-02-28 16:09 ET
Crinetics Pharmaceuticals published news for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q4
SEC form 10
2023-11-07 16:11 ET
Crinetics Pharmaceuticals reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q3
SEC form 8
2023-11-07 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q3
SEC form 10
2023-08-08 07:07 ET
Crinetics Pharmaceuticals reported for 2023 q2
SEC form 6
2023-08-08 07:01 ET
Crinetics Pharmaceuticals reported for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q2
SEC form 8
2023-08-08 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q2
SEC form 6
2023-06-21 16:36 ET
Crinetics Pharmaceuticals published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q1
SEC form 8
2023-05-04 00:00 ET
Crinetics Pharmaceuticals reported for 2023 q1
SEC form 6
2023-03-13 08:30 ET
Crinetics Pharmaceuticals published news for 2022 q4
SEC form 10
2023-02-28 16:26 ET
Crinetics Pharmaceuticals reported for 2022 q4
SEC form 6
2023-02-28 16:13 ET
Crinetics Pharmaceuticals reported for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Crinetics Pharmaceuticals reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Crinetics Pharmaceuticals reported for 2022 q4
SEC form 6
2023-01-09 08:43 ET
Crinetics Pharmaceuticals published news for 2022 q4
SEC form 6
2022-11-28 08:32 ET
Crinetics Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-14 08:31 ET
Crinetics Pharmaceuticals reported for 2022 q3
SEC form 6
2022-11-14 08:15 ET
Crinetics Pharmaceuticals published news for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Crinetics Pharmaceuticals reported for 2022 q3
SEC form 8
2022-11-14 00:00 ET
Crinetics Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-13 08:32 ET
Crinetics Pharmaceuticals published news for 2022 q3
SEC form 6
2022-10-03 08:30 ET
Crinetics Pharmaceuticals published news for 2022 q3
SEC form 6
2022-09-14 18:08 ET
Crinetics Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-12 08:46 ET
Crinetics Pharmaceuticals published news for 2022 q2
SEC form 6
2022-08-12 08:41 ET
Crinetics Pharmaceuticals published news for 2022 q2
SEC form 10
2022-08-12 00:00 ET
Crinetics Pharmaceuticals reported for 2022 q2
SEC form 8
2022-08-12 00:00 ET
Crinetics Pharmaceuticals published news for 2022 q2
SEC form 6
2022-06-21 16:31 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-25 07:02 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-12 16:49 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 6
2022-05-12 16:40 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Crinetics Pharmaceuticals reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-28 16:50 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 6
2022-04-13 16:26 ET
Crinetics Pharmaceuticals published news for 2022 q1
SEC form 10
2022-03-30 16:12 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-30 16:05 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 10
2022-03-30 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 8
2022-03-30 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-25 17:00 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-17 18:22 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-14 09:01 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-03-01 08:00 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-02-28 08:30 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-12 07:35 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2022-01-05 17:00 ET
Crinetics Pharmaceuticals published news for 2021 q4
SEC form 6
2021-12-23 16:30 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-08 08:53 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-05 08:02 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 6
2021-11-05 08:00 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 10
2021-11-05 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 8
2021-11-05 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-21 16:24 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-20 16:19 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 8
2021-10-20 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 6
2021-10-18 16:08 ET
Crinetics Pharmaceuticals published news for 2021 q3
SEC form 6
2021-09-27 07:54 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 6
2021-09-15 16:05 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 6
2021-09-02 17:00 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 6
2021-09-02 17:00 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-10 16:09 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 6
2021-08-10 16:05 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 10
2021-08-10 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 8
2021-08-10 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 6
2021-07-29 16:15 ET
Crinetics Pharmaceuticals published news for 2021 q2
SEC form 6
2021-06-28 07:30 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 6
2021-06-23 16:55 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 16:01 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 6
2021-05-06 16:01 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-29 18:16 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 6
2021-04-08 16:09 ET
Crinetics Pharmaceuticals published news for 2021 q1
SEC form 10
2021-03-30 17:12 ET
Crinetics Pharmaceuticals published news for 2020 q4
SEC form 6
2021-03-30 17:05 ET
Crinetics Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-04 07:00 ET
Crinetics Pharmaceuticals published news for 2020 q4
SEC form 6
2021-02-03 07:00 ET
Crinetics Pharmaceuticals published news for 2020 q4
SEC form 6
2021-01-06 07:00 ET
Crinetics Pharmaceuticals published news for 2020 q4
SEC form 10
2020-11-06 08:33 ET
Crinetics Pharmaceuticals published news for 2020 q3
SEC form 6
2020-11-06 08:30 ET
Crinetics Pharmaceuticals published news for 2020 q3
SEC form 6
2020-10-26 06:55 ET
Crinetics Pharmaceuticals published news for 2020 q3